Entrada Therapeutics, Inc. (TRDA)
5.25
+0.56
(+11.94%)
USD |
NASDAQ |
Nov 10, 16:00
5.255
0.00 (0.00%)
After-Hours: 20:00
Entrada Therapeutics Net Income (Quarterly) : -39.74M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -39.74M |
| June 30, 2026 | -42.76M |
| March 31, 2026 | -39.72M |
| December 31, 2025 | -39.16M |
| September 30, 2025 | -44.13M |
| June 30, 2025 | -43.10M |
| March 31, 2025 | -17.35M |
| December 31, 2024 | 1.131M |
| September 30, 2024 | -14.03M |
| June 30, 2024 | 55.03M |
| March 31, 2024 | 23.50M |
| December 31, 2023 | -9.544M |
| September 30, 2023 | 35.46M |
| Date | Value |
|---|---|
| June 30, 2023 | -25.93M |
| March 31, 2023 | -6.674M |
| December 31, 2022 | -24.63M |
| September 30, 2022 | -25.14M |
| June 30, 2022 | -23.18M |
| March 31, 2022 | -21.67M |
| December 31, 2021 | -18.45M |
| September 30, 2021 | -14.43M |
| June 30, 2021 | -9.901M |
| March 31, 2021 | -8.38M |
| December 31, 2020 | -8.673M |
| September 30, 2020 | -6.99M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Prime Medicine, Inc. | -42.11M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -28.46M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.905M |
| Total Expenses (Quarterly) | 40.65M |
| EPS Diluted (Quarterly) | -0.9379 |
| Enterprise Value | 59.84M |
| Gross Profit Margin (Quarterly) | 22.65% |
| Profit Margin (Quarterly) | -4.39K% |
| Earnings Yield | -73.17% |
| Normalized Earnings Yield | -73.17 |